Joslin Diabetes Center and Diabetica Research Solutions join to raise diabetes awareness

Joslin Diabetes Center (Joslin), the world-renowned leader in diabetes research and clinical care, and Diabetica Research Solutions, Inc. (DRSI), makers of drsi™ ReStore! Energy, the only energy and hydration formula specifically designed for the needs of people with diabetes, today announced they will work together to support diabetes causes and programs to which they are deeply committed, and help to educate others and raise awareness about diabetes, its causes and solutions, throughout the world.

Founded in 1898, Joslin Diabetes Center, which is affiliated with Harvard Medical School, and its 28 affiliated centers, is the world’s preeminent diabetes research and clinical care organization. DRSI is a Florida based private company focusing on consumer healthcare products to help people live better with diabetes. The company has recently introduced its flagship product drsi™ ReStore! Energy in a nationwide launch.

The two organizations will develop philanthropic opportunities to help expand diabetes awareness. Michael P. Sullivan, SVP with Joslin said, “With over 177 million people globally including 25 million in the U.S. believed to have diabetes, and millions more at risk, it is critical for Joslin to find ways to bring new solutions to large populations of people. By offering consumers information, guidance, tools, and services through a joint effort with DRSI, Joslin is able to fulfill its mission with greater scale.”

“Partnering with a prestigious organization such as Joslin Diabetes Center will help spread a message within our target market that there is hope for people with diabetes in battling fatigue and help them get more out of each day,” said DRSI CEO Younis Zubchevich. “Our plans are to work hand in hand to help Joslin philanthropically and with education, bring hope and relief to people with diabetes that they too can live each day to its fullest.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SGLT2 inhibitor canagliflozin shown to improve kidney oxygenation in diabetes patients